Organon & Co banner

Organon & Co
XMUN:7XP

Watchlist Manager
Organon & Co Logo
Organon & Co
XMUN:7XP
Watchlist
Price: 6.26 EUR 0.38% Market Closed
Market Cap: €1.6B

Relative Value

The Relative Value of one 7XP stock under the Base Case scenario is hidden EUR. Compared to the current market price of 6.26 EUR, Organon & Co is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

7XP Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Multiples Across Competitors

7XP Competitors Multiples
Organon & Co Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Organon & Co
XMUN:7XP
2.1B EUR 0.3 4.2 6 7.5
US
Eli Lilly and Co
NYSE:LLY
959.3B USD 14.7 46.5 31.3 33.3
US
Johnson & Johnson
NYSE:JNJ
585.3B USD 6.2 21.8 15.2 18.6
CH
Roche Holding AG
SIX:ROG
291.8B CHF 4.8 31.1 13.1 15.3
UK
AstraZeneca PLC
LSE:AZN
238.2B GBP 5.5 31.6 17.4 24.6
CH
Novartis AG
SIX:NOVN
242.2B CHF 5.5 22.2 13.7 17.6
US
Merck & Co Inc
NYSE:MRK
305.1B USD 4.7 16.7 10.4 12.2
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 333.1 835.4
DK
Novo Nordisk A/S
CSE:NOVO B
1.3T DKK 4.3 13 9.5 11.2
US
Pfizer Inc
NYSE:PFE
151.4B USD 2.4 19.5 7.3 9.7
UK
GSK plc
XETRA:GS71
103.6B EUR 2.8 15.8 8 11.3
P/S Multiple
Revenue Growth P/S to Growth
US
Organon & Co
XMUN:7XP
Average P/S: 13.2
0.3
-1%
N/A
US
Eli Lilly and Co
NYSE:LLY
14.7
19%
0.8
US
Johnson & Johnson
NYSE:JNJ
6.2
6%
1
CH
Roche Holding AG
SIX:ROG
4.8
3%
1.6
UK
AstraZeneca PLC
LSE:AZN
5.5
7%
0.8
CH
Novartis AG
SIX:NOVN
5.5
5%
1.1
US
Merck & Co Inc
NYSE:MRK
4.7
5%
0.9
IE
E
Endo International PLC
LSE:0Y5F
94
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
4.3
3%
1.4
US
Pfizer Inc
NYSE:PFE
2.4
-4%
N/A
UK
GSK plc
XETRA:GS71
2.8
5%
0.6
P/E Multiple
Earnings Growth PEG
US
Organon & Co
XMUN:7XP
Average P/E: 22.2
4.2
7%
0.6
US
Eli Lilly and Co
NYSE:LLY
46.5
28%
1.7
US
Johnson & Johnson
NYSE:JNJ
21.8
7%
3.1
CH
Roche Holding AG
SIX:ROG
31.1
29%
1.1
UK
AstraZeneca PLC
LSE:AZN
31.6
26%
1.2
CH
Novartis AG
SIX:NOVN
22.2
15%
1.5
US
Merck & Co Inc
NYSE:MRK
16.7
14%
1.2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
13
7%
1.9
US
Pfizer Inc
NYSE:PFE
19.5
26%
0.7
UK
GSK plc
XETRA:GS71
15.8
18%
0.9
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Organon & Co
XMUN:7XP
Average EV/EBITDA: 42.3
6
5%
1.2
US
Eli Lilly and Co
NYSE:LLY
31.3
18%
1.7
US
Johnson & Johnson
NYSE:JNJ
15.2
2%
7.6
CH
Roche Holding AG
SIX:ROG
13.1
5%
2.6
UK
AstraZeneca PLC
LSE:AZN
17.4
11%
1.6
CH
Novartis AG
SIX:NOVN
13.7
9%
1.5
US
Merck & Co Inc
NYSE:MRK
10.4
7%
1.5
IE
E
Endo International PLC
LSE:0Y5F
333.1
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
9.5
7%
1.4
US
Pfizer Inc
NYSE:PFE
7.3
-4%
N/A
UK
GSK plc
XETRA:GS71
8
2%
4
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Organon & Co
XMUN:7XP
Average EV/EBIT: 90.6
7.5
7%
1.1
US
Eli Lilly and Co
NYSE:LLY
33.3
17%
2
US
Johnson & Johnson
NYSE:JNJ
18.6
6%
3.1
CH
Roche Holding AG
SIX:ROG
15.3
6%
2.5
UK
AstraZeneca PLC
LSE:AZN
24.6
24%
1
CH
Novartis AG
SIX:NOVN
17.6
12%
1.5
US
Merck & Co Inc
NYSE:MRK
12.2
6%
2
IE
E
Endo International PLC
LSE:0Y5F
835.4
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
11.2
8%
1.4
US
Pfizer Inc
NYSE:PFE
9.7
-1%
N/A
UK
GSK plc
XETRA:GS71
11.3
12%
0.9